Serum lipids and age-related lens opacities: A longitudinal investigation: The Framingham studies

Ophthalmology

Volumn 110, Issue 3, 2003, Pages 578-583

  Hiller, Rita ^a,e   Sperduto, Robert D ^a   Reed, George F ^a   D'Agostino, Ralph B ^b   Wilson, Peter W F ^c,d  

^a NATIONAL EYE INSTITUTE   (United States)

^b Boston University   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d FRAMINGHAM HEART STUDY   (United States)

^e Division of Epidemiology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; AGE; ARTICLE; CATARACT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0037370430     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-6420(02)01762-1     Document Type: Article

References (39)

1. Klein BEK, Klein R, Lee KE. Cardiovascular disease, selected cardiovascular disease risk factors, and age-related cataracts: the Beaver Dam Eye Study. Am J Ophthalmol 1997;123:338-46.
2. Klein BEK, Klein R, Lee KE. Diabetes, cardiovascular disease, selected cardiovascular disease risk factors, and the 5-year incidence of age-related cataract and progression of lens opacities: the Beaver Dam Eye Study. Am J Ophthalmol 1998;126:782-90.
3. Goodrich ME, Cumming RG, Mitchell P, et al. Plasma fibrinogen and other cardiovascular disease risk factors and cataract. Ophthalmic Epidemiol 1999;6:279-90.
4. Jahn CE, Janke M, Winowski H, et al. Identification of metabolic risk factors for posterior subcapsular cataract. Ophthalmic Res 1986;18:112-6.
5. Miglior S, Bergamini F, Migliavacca L, et al. Metabolic and social risk factors in a cataractous population. A case-control study. Dev Ophthalmol 1989;17:158-64.
6. Marks RG, Hale WE, Perkins LL, et al. Cataracts in Dunedin program participants: an evaluation of risk factors. J Cataract Refract Surg 1988;14:58-63.
7. Clayton RM, Cuthbert J, Duffy J, et al. Some risk factors associated with cataract in S. E. Scotland: A pilot study. Trans Ophthalmol Soc U K 1982;102:331-6.
8. Knekt P, Heliövaara M, Rissanen A, et al. Serum antioxidant vitamins and risk of cataract. BMJ 1992;305:1392-4.
9. West S, Munoz B, Emmett EA, Taylor HR. Cigarette smoking and risk of nuclear cataracts. Arch Ophthalmol 1989;107:1166-9.
10. Solberg Y, Rosner M, Belkin M. The association between cigarette smoking and ocular diseases. Surv Ophthalmol 1998;42:535-47.
11. Hiller R, Sperduto RD, Podgor MJ, et al. Cigarette smoking and the risk of development of lens opacities. The Framingham Studies. Arch Ophthalmol 1997;115:1113-8.
12. Glynn RJ, Christen WG, Manson JE, et al. Body mass index. An independent predictor of cataract. Arch Ophthalmol 1995;113:1131-7.
13. Hiller R, Podgor MJ, Sperduto RD, et al. A longitudinal study of body mass index and lens opacities. The Framingham Studies. Ophthalmology 1998;105:1244-50.
14. Ederer F, Hiller R, Taylor HR. Senile lens changes and diabetes in two population studies. Am J Ophthalmol 1981;91:381-95.
15. Hiller R, Sperduto RD, Ederer F. Epidemiologic associations with nuclear, cortical, and posterior subcapsular cataracts. Am J Epidemiol 1986;124:916-25.
16. Leske MC, Chylack LT Jr, Wu SY. The Lens Opacities Case-Control Study. Risk factors for cataract. Arch Ophthalmol 1991;109:244-51.
17. Klein BEK, Klein R, Jensen SC, Linton KLP. Hypertension and lens opacities from the Beaver Dam Eye Study. Am J Ophthalmol 1995;119:640-6.
18. Kahn HA, Leibowitz HM, Ganley JP, et al. The Framingham Eye Study. II. Association of ophthalmic pathology with single variables previously measured in the Framingham Eye Study. Am J Epidemiol 1977;106:33-41.
19. Risk factors associated with age-related nuclear and cortical cataract. A case-control study in the Age-Related Eye Disease Study, AREDS Report No. 5. Age-Related Eye Disease Study Research Group. Ophthalmology 2001;108:1400-8.
20. West SK, Muñoz B, Istre J, et al. Mixed lens opacities and subsequent mortality. Arch Ophthalmol 2000;118:393-7.
21. Klein R, Klein BEK, Moss SE. Age-related eye disease and survival. The Beaver Dam Eye Study. Arch Ophthalmol 1995;113:333-9.
22. Ninn-Pedersen KN, Stenevi U. Cataract patients in a defined Swedish population 1986-90: VII inpatient and outpatient standardized mortality ratios. Br J Ophthalmol 1995;79:1115-9.
23. Dawber TR, Meadors GF, Moore FE Jr. Epidemiological approaches to heart disease: the Framingham Study. Am J Public Health 1951;41:279-86.
24. Kannel WB, Feinleib M, McNamara PM, et al. An investigation of coronary heart disease in families. The Framingham Offspring Study. Am J Epidemiol 1979;110:281-90.
25. Familial aggregation of lens opacities: the Framingham Eye Study and the Framingham Offspring Eye Study. The Framingham Offspring Eye Study Group. Am J Epidemiol 1994;140:555-64.
26. Taylor HR, West SK. The clinical grading of lens opacities. Aust N Z J Ophthalmol 1989;17:81-6.
27. Abell LL, Levy BB, Brodie BB, Kendall FE. A simplified method for the estimation of total cholesterol in serum and demonstration of its specificity. J Biol Chem 1952;195:357-66.
28. Kessler G, Lederer H. Fluorometric measurements of triglycerides. In: Skeggs LT Jr, ed. Automation in Analytical Chemistry (Technicon Symposium). New York: Mediad, 1965; v. 1, 341-53.
29. Manual of Laboratory Operations: Lipid Research Clinics Program. Bethesda, MD: National Heart and Lung Institute, NIH, 1974. DHEW Pub. No. 75-628, 51-59.
30. Wilson PWF, Christiansen JC, Anderson KM, Kannel WB. Impact of national guidelines for cholesterol risk factor screening. The Framingham Offspring Study. JAMA 1989;262:41-4.
31. 2+ precipitation procedure for quantitation of high-density lipoprotein cholesterol. Clin Chem 1982;28:1379-88.
32. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
33. Lissner L, Odell PM, D'Agostino RB, et al. Variability of body weight and health outcomes in the Framingham population. N Engl J Med 1991;324:1839-44.
34. Dellinger EP. Variability of body weight and health outcomes [letter]. N Engl J Med 1991;325:1745.
35. Patsch W, Sharrett AR, Sorlie PD, et al. The relation of high density lipoprotein cholesterol and its subfractions to apolipoprotein A-1 and fasting triglycerides: the role of environmental factors. The Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol 1992;136:546-57.
36. Grundy SM. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol 1999;83:25F-29F.
37. Brewer HB Jr. Hypertriglyceridemia: changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease. Am J Cardiol 1999;83:3F-12F.
38. Dixon WJ. BMDP Statistical Software Manual. Berkeley: University of California Press, 1992; v.2.
39. Tsutsumi K, Inoue Y, Yoshida C. Acceleration of development of diabetic cataract by hyperlipidemia and low high-density lipoprotein in rats. Biol Pharm Bull 1999;22:37-41.